

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following progression-free survival outcomes was reported in the Phase III ENDURANCE (ECOG-E1A11) trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (RVd) as initial therapy for patients with newly diagnosed multiple myeloma (MM)?**
 - a. KRd was inferior to RVd
 - b. KRd was noninferior/equivalent to RVd**
 - c. KRd was superior to RVd
- 2. What was observed in the Phase II DREAMM-6 study evaluating the anti-B-cell maturation antigen (anti-BCMA) antibody-drug conjugate belantamab mafodotin in combination with bortezomib/dexamethasone for patients with relapsed/refractory MM?**
 - a. Unacceptably high rates of Grade 5 adverse events
 - b. A low overall response rate (<10%)
 - c. Frequent ocular toxicities**
- 3. What is the target of the CAR (chimeric antigen receptor) T-cell therapy evaluated in the pivotal Phase II KarMMa study for patients with MM?**
 - a. CD19
 - b. BCMA**
 - c. CD20
- 4. Which of the following drug types best describes the mechanism of action of the novel agent CC-92480?**
 - a. Anti-CD38 antibody
 - b. Bcl-2-targeted agent
 - c. BCMA-targeted agent
 - d. CELMoD (cereblon E3 ligase modulator)**